

Dimpy P Shah

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1926034/publications.pdf>

Version: 2024-02-01

68
papers

3,723
citations

218677
26
h-index

138484
58
g-index

70
all docs

70
docs citations

70
times ranked

7506
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. JAMA Network Open, 2022, 5, e2142046.	5.9	9
2	Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer. IScience, 2022, 25, 103699.	4.1	5
3	Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study. Open Forum Infectious Diseases, 2022, 9, ofac037.	0.9	8
4	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. JAMA Network Open, 2022, 5, e224304.	5.9	43
5	Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. Blood Cancer Discovery, 2022, 3, 181-193.	5.0	12
6	COVID-19 vaccine effectiveness in patients with hematologic malignancy. Transplant Infectious Disease, 2022, 24, .	1.7	1
7	Comparison of rectal swab, glove tip, and participant-collected stool techniques for gut microbiome sampling. BMC Microbiology, 2021, 21, 26.	3.3	14
8	Humoral and Mucosal Antibody Response to RSV Structural Proteins in RSV-Infected Adult Hematopoietic Cell Transplant (HCT) Recipients. Viruses, 2021, 13, 991.	3.3	1
9	Care without a compass: Including patients with cancer in COVID-19 studies. Cancer Cell, 2021, 39, 895-896.	16.8	14
10	Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell, 2021, 39, 1091-1098.e2.	16.8	199
11	The COVID-19 risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19. Journal of Thrombosis and Haemostasis, 2021, 19, 2522-2532.	3.8	23
12	Mucormycosis in Hematopoietic Cell Transplant Recipients and in Patients With Hematological Malignancies in the Era of New Antifungal Agents. Open Forum Infectious Diseases, 2021, 8, ofaa646.	0.9	17
13	Antigenic Fingerprinting of Respiratory Syncytial Virus (RSV)-Infected Hematopoietic Cell Transplant Recipients Reveals Importance of Mucosal Anti-RSV G Antibodies in Control of RSV Infection in Humans. Journal of Infectious Diseases, 2020, 221, 636-646.	4.0	14
14	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. Cancer Discovery, 2020, 10, 1514-1527.	9.4	108
15	Oral microbiome and onset of oral mucositis in patients with squamous cell carcinoma of the head and neck. Cancer, 2020, 126, 5124-5136.	4.1	30
16	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. Cancer Cell, 2020, 38, 761-766.	16.8	26
17	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet, The, 2020, 395, 1907-1918.	13.7	1,395
18	Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study. Clinical Infectious Diseases, 2020, 71, 2365-2374.	5.8	36

#	ARTICLE	IF	CITATIONS
19	Antibody Response to the Furin Cleavable Twenty-Seven Amino Acid Peptide (p27) of the Fusion Protein in Respiratory Syncytial Virus (RSV) Infected Adult Hematopoietic Cell Transplant (HCT) Recipients. <i>Vaccines</i> , 2020, 8, 192.	4.4	7
20	Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz173.	0.9	32
21	Metformin modifies disparity in hepatocellular carcinoma incidence in men with type 2 diabetes but without chronic liver diseases. <i>Cancer Medicine</i> , 2019, 8, 3206-3215.	2.8	9
22	Receptor tyrosine kinase recepteur d'origine nantais as predictive marker for aggressive prostate cancer in African Americans. <i>Molecular Carcinogenesis</i> , 2019, 58, 854-861.	2.7	7
23	Antigenic Site-Specific Competitive Antibody Responses to the Fusion Protein of Respiratory Syncytial Virus Were Associated With Viral Clearance in Hematopoietic Cell Transplantation Adults. <i>Frontiers in Immunology</i> , 2019, 10, 706.	4.8	13
24	Pulmonary Impairment after Respiratory Viral Infections Is Associated with High Mortality in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 800-809.	2.0	22
25	The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2019, 219, 898-907.	4.0	52
26	Comparison of Palivizumab-Like Antibody Binding to Different Conformations of the RSV F Protein in RSV-Infected Adult Hematopoietic Cell Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2018, 217, 1247-1256.	4.0	17
27	Influenza in patients with hematological malignancies: Experience at two comprehensive cancer centers. <i>Journal of Medical Virology</i> , 2018, 90, 50-60.	5.0	25
28	Risk factors for mortality after respiratory syncytial virus lower respiratory tract infection in adults with hematologic malignancies. <i>Transplant Infectious Disease</i> , 2018, 20, e12994.	1.7	26
29	Outcomes of Resistant or Refractory CMV Infection in Recipients of Allogeneic Hematopoietic Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S385-S386.	2.0	0
30	Leukopenia and lack of ribavirin predict poor outcomes in patients with haematological malignancies and respiratory syncytial virus infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3162-3169.	3.0	7
31	Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer. <i>European Urology</i> , 2018, 74, 575-582.	1.9	117
32	Progression of the Radiologic Severity Index predicts mortality in patients with parainfluenza virus-associated lower respiratory infections. <i>PLoS ONE</i> , 2018, 13, e0197418.	2.5	19
33	Burden of human metapneumovirus infections in patients with cancer: Risk factors and outcomes. <i>Cancer</i> , 2017, 123, 2329-2337.	4.1	25
34	The Impact of Pre- and Week 4 Post-Transplant CMV-Specific Elispot Assay on CMV Reactivation and Survival in CMV-Seropositive Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S47-S48.	2.0	0
35	Drug-Resistant Cytomegalovirus Infections in Hematopoietic Cell Transplant Recipients: A Single Center Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S188-S189.	2.0	0
36	How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. <i>Blood</i> , 2016, 128, 2624-2636.	1.4	140

#	ARTICLE	IF	CITATIONS
37	Association of increased influenza vaccination in health care workers with a reduction in nosocomial influenza infections in cancer patients. <i>American Journal of Infection Control</i> , 2016, 44, 1016-1021.	2.3	63
38	Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience. <i>Antiviral Research</i> , 2016, 134, 58-62.	4.1	37
39	Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series. <i>Antiviral Research</i> , 2016, 135, 91-96.	4.1	20
40	Challenges in Determining Genotypes for Pharmacogenetics in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 638-642.	2.8	3
41	The Economic and Clinical Burden of Respiratory Viral Infections in Hematopoietic Cell Transplant (HCT) Recipients: A Cost Comparison Study Across 19 Major Cancer Centers in the U. S. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S53.	2.0	2
42	Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review. <i>Cancer Letters</i> , 2016, 379, 100-106.	7.2	56
43	Knowledge, Attitude, and Practices Regarding Occupational HIV Exposure and Protection among Health Care Workers in China. <i>Journal of the International Association of Providers of AIDS Care</i> , 2016, 15, 363-369.	1.5	15
44	Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review. <i>Cancer Letters</i> , 2016, 370, 358-364.	7.2	86
45	The Utility of Interferon-Gamma Release Assays (IGRAs) for the Diagnosis of Mycobacterium Tuberculosis (Mtb) in Hematopoietic Cell Transplant (HCT) Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S175.	2.0	0
46	Utility of the Enzyme-Linked Immunospot Interferon- γ Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2016, 213, 1701-1707.	4.0	63
47	An Open Label, Block-Randomized, Ribavirin Efficacy Trial for Management of RSV Infections in Hematopoietic Cell Transplant (HCT) Recipients: Clinical and Economic Implications. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S52-S53.	2.0	2
48	Outcomes of Influenza Infections in Hematopoietic Cell Transplant Recipients: Application of an Immunodeficiency Scoring Index. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 542-548.	2.0	68
49	Influenza Vaccination in Patients With Cancer: Factors Associated With Vaccination Practices for Patients and Their Household Members. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 1239-1241.	1.8	7
50	Long-Term Effectiveness of Accelerated Hepatitis B Vaccination Schedule in Drug Users. <i>American Journal of Public Health</i> , 2015, 105, e36-e43.	2.7	21
51	Infection With Novel Respiratory Syncytial Virus Genotype Ontario (ON1) in Adult Hematopoietic Cell Transplant Recipients, Texas, 2011-2013. <i>Journal of Infectious Diseases</i> , 2015, 211, 582-589.	4.0	43
52	Fecal colonization and infection with <i>Pseudomonas aeruginosa</i> in recipients of allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2015, 17, 33-38.	1.7	48
53	Cluster and Sporadic Cases of <i>Herbaspirillum</i> Species Infections in Patients With Cancer. <i>Clinical Infectious Diseases</i> , 2015, 60, 48-54.	5.8	21
54	Vaccination guidelines after hematopoietic stem cell transplantation: practitioners' knowledge, attitudes, and gap between guidelines and clinical practice. <i>Transplant Infectious Disease</i> , 2014, 16, 878-886.	1.7	41

#	ARTICLE	IF	CITATIONS
55	Management of Respiratory Viral Infections in Hematopoietic Cell Transplant Recipients and Patients With Hematologic Malignancies. <i>Clinical Infectious Diseases</i> , 2014, 59, S344-S351.	5.8	172
56	Utility of routine surveillance blood cultures in asymptomatic allogeneic hematopoietic stem cell transplant recipients with indwelling central venous catheters at a comprehensive cancer center. <i>American Journal of Infection Control</i> , 2014, 42, 1084-1088.	2.3	13
57	Immune response to hepatitis B vaccination in drug using populations: A systematic review and meta-regression analysis. <i>Vaccine</i> , 2014, 32, 2265-2274.	3.8	31
58	Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. <i>Blood</i> , 2014, 123, 3263-3268.	1.4	110
59	Respiratory Syncytial Virus Infections in Children With Cancer. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, e376-e381.	0.6	20
60	Differentially regulated gene expression associated with hepatitis C virus clearance. <i>Journal of General Virology</i> , 2013, 94, 534-542.	2.9	8
61	Reply to FÄtkenheuer et al. <i>Journal of Infectious Diseases</i> , 2013, 207, 1622-1623.	4.0	0
62	Reply to Robinson. <i>Journal of Infectious Diseases</i> , 2013, 208, 864-865.	4.0	0
63	Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1872-1880.	3.0	125
64	Comparison of long-term immunogenicity (23 y) of 10 $\hat{1}$ / ₄ g and 20 $\hat{1}$ / ₄ g doses of hepatitis B vaccine in healthy children. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1071-1076.	3.3	11
65	An Adaptive Randomized Trial of an Intermittent Dosing Schedule of Aerosolized Ribavirin in Patients With Cancer and Respiratory Syncytial Virus Infection. <i>Journal of Infectious Diseases</i> , 2012, 206, 1367-1371.	4.0	52
66	Characteristics and Outcomes of Pandemic 2009/H1N1 Versus Seasonal Influenza in Children With Cancer. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 373-378.	2.0	24
67	Demographics, socioâ€behavioral factors, and drug use patterns: What matters in spontaneous HCV clearance?. <i>Journal of Medical Virology</i> , 2012, 84, 235-241.	5.0	12
68	Management of respiratory viral infections in hematopoietic cell transplant recipients. <i>American Journal of Blood Research</i> , 2012, 2, 203-18.	0.6	60